Drug application
IOBENGUANE I-123 (IOBENGUANE SULFATE I-123)
Drugs@FDA ANDA 213637 · BWXT MEDCL
Key facts
| Drug name | IOBENGUANE I-123 |
|---|---|
| Active ingredients | IOBENGUANE SULFATE I-123 |
| Application type | ANDA |
| Application number | 213637 |
| Company | BWXT MEDCL |
| Dosage forms | SOLUTION, INTRAVENOUS |
| Strength | 10mCi/5ML (2mCi/ML) |
| Marketing status | Discontinued |
| TE codes | AP |
| Reference listed drug | No |
| Latest submission status date | Dec 9, 2024 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: